ADTX: Aditxt, Inc. Stock

by  •  • Comments Off on ADTX: Aditxt, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.78
Enterprise Value ($M) 19.85
Book Value ($M) 16.05
Book Value / Share 9.64
Price / Book 0.24
NCAV ($M) -21.62
NCAV / Share -12.98
Price / NCAV -0.17

Profitability (mra)
Return on Invested Capital (ROIC) -0.95
Return on Assets (ROA) -4.24
Return on Equity (ROE) -475.71

Liquidity (mrq)
Quick Ratio 0.24
Current Ratio 0.27

Balance Sheet (mrq) ($M)
Current Assets 6.91
Assets 44.58
Liabilities 28.53
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.65
Operating Income -26.06
Net Income -32.38

Cash Flow Statement (mra) ($M)
Cash From Operations -18.58
Cash from Investing -0.01
Cash from Financing 15.92

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A CVI Investments, Inc. 0.50
02-06 13G/A Intracoastal Capital, Llc 1.50
01-02 13G/A Sabby Management, Llc 4.99 -94.70

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-07-12 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PU
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P
2023-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 2,649 26,064 10.16
2024-04-23 1,762 21,697 8.12
2024-04-22 4,974 57,128 8.71
2024-04-19 1,275 6,008 21.22

(click for more detail)

Similar Companies
ACST – Acasti Pharma Inc. ACXP – Acurx Pharmaceuticals, Inc.
ADIL – Adial Pharmaceuticals, Inc. ADVM – Adverum Biotechnologies, Inc.
AEZS – Aeterna Zentaris Inc.


Financial data and stock pages provided by
Fintel.io